...
首页> 外文期刊>Journal of Medicinal Chemistry >Discovery of 7-Oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships
【24h】

Discovery of 7-Oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships

机译:发现7-氧代-2,4,5,7-四氢-6H-吡唑[3,4-C]吡啶衍生物作为有效的,口服和脑穿透受体相互作用蛋白1(RIP1)激酶抑制剂:分析 结构 - 动态关系

获取原文
获取原文并翻译 | 示例
           

摘要

We report the discovery of 7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine derivatives as a novel class of receptor interacting protein 1 (RIP1) kinase inhibitors. On the basis of the overlay study between HTS hit 10 and GSK2982772 (6) in RIP1 kinase, we designed and synthesized a novel class of RIP1 kinase inhibitor 11 possessing moderate RIP1 kinase inhibitory activity and P-gp mediated efflux. The optimization of the core structure and the exploration of appropriate substituents utilizing SBDD approach led to the discovery of 22, a highly potent, orally available, and brain-penetrating RIP1 kinase inhibitor with excellent PK profiles. Compound 22 significantly suppressed necroptotic cell death both in mouse and human cells. Oral administration of 22 (10 mg/kg, bid) attenuated disease progression in the mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (MS). Moreover, analysis of structure kinetic relationship (SKR) for our novel chemical series was also discussed.
机译:我们报告了7-氧代-2,4,5,7-四氢-6H-吡唑[3,4-C]吡啶衍生物作为一种新型受体相互作用蛋白1(RIP1)激酶抑制剂的发现。在RIP1激酶中HTS HET 10和GSK2982772(6)之间的覆盖研究的基础上,我们设计并合成了一种具有中度RIP1激酶抑制活性和P-GP介导的Efflux的一种新型的RIP1激酶抑制剂11。利用SBDD方法的核心结构的优化和对适当取代基的探索引起了22,高效,口服可用的,具有优异的PK型材的脑穿透裂纹1激酶抑制剂。化合物22在小鼠和人细胞中显着抑制了肮脏的细胞死亡。在多发性硬化症(MS)的小鼠实验自身免疫脑脊髓炎(EAE)模型中,口服给药22(10mg / kg,出价)减毒进展。此外,还讨论了对我们新型化学系列的结构动力学关系(SKR)分析。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2018年第6期|共26页
  • 作者单位

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut 10410 Sci Ctr Dr San Diego CA 92121 USA;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut 10410 Sci Ctr Dr San Diego CA 92121 USA;

    Takeda Pharmaceut 10410 Sci Ctr Dr San Diego CA 92121 USA;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

    Takeda Pharmaceut Co Ltd Res 26-1 Muraoka Higashi 2 Chome Fujisawa Kanagawa 2518555 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号